Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis

Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine

(2016) Nicholas Wettersten et al.   AMERICAN JOURNAL OF MEDICINE

Galectin-3 in Renal Pathology: More Than Just an Innocent Bystander?

(2016) Valérie Desmedt et al.   AMERICAN JOURNAL OF NEPHROLOGY

Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation

(2016) Ellie Coromilas et al.   BMC Cardiovascular Disorders

Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis

(2016) Fahmy T. Ali et al.   CLINICA CHIMICA ACTA

Diagnosing sepsis – The role of laboratory medicine

(2016) Shu-Ling Fan et al.   CLINICA CHIMICA ACTA

Combined biomarkers discriminate a low likelihood of bacterial infection among surgical intensive care unit patients with suspected sepsis

(2016) Brendan J. Kelly et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

(2016) Mervyn Singer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Interleukin 6, galectin 3, growth differentiation factor 15, and soluble ST2 for mortality prediction in critically ill patients

(2016) Benjamin Dieplinger et al.   JOURNAL OF CRITICAL CARE

Diagnostic accuracy of presepsin (sCD14-ST) and procalcitonin for prediction of bacteraemia and bacterial DNAaemia in patients with suspected sepsis

(2016) Christian Leli et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial

(2016) Evelien de Jong et al.   LANCET INFECTIOUS DISEASES

Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and community-acquired pneumonia in ICU patients

(2016) Kada Klouche et al.   Annals of Intensive Care

Multi-Marker Strategy in Heart Failure: Combination of ST2 and CRP Predicts Poor Outcome

(2016) Anne Marie Dupuy et al.   PLoS One

Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases

(2015) Thomas Mueller et al.   CLINICA CHIMICA ACTA

Soluble ST2 Has a Prognostic Role in Patients With Suspected Sepsis

(2015) Mina Hur et al.   Annals of Laboratory Medicine

Accuracy of Presepsin in Sepsis Diagnosis: A Systematic Review and Meta-Analysis

(2015) Jiayuan Wu et al.   PLoS One

Diagnostic and prognostic utilities of multimarkers approach using procalcitonin, B-type natriuretic peptide, and neutrophil gelatinase-associated lipocalin in critically ill patients with suspected sepsis

(2014) Mina Hur et al.   BMC INFECTIOUS DISEASES

Galectin-3 testing: Validity of a novel automated assay in heart failure patients with reduced ejection fraction

(2013) D. Gruson et al.   CLINICA CHIMICA ACTA

Circulating galectin-3 in infections and non-infectious inflammatory diseases

(2013) J. Oever et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012

(2013) R. P. Dellinger et al.   INTENSIVE CARE MEDICINE

2013 ACCF/AHA Guideline for the Management of Heart Failure

(2013) Clyde W. Yancy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The Presage®ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2

(2012) Thomas Mueller et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Development of a point-of-care assay system for measurement of presepsin (sCD14-ST)

(2011) Yoshikazu Okamura et al.   CLINICA CHIMICA ACTA

Current management of sepsis in critically ill adult patients

(2011) Jean-Louis Vincent et al.   Expert Review of Anti-Infective Therapy